Evidence map›Paper›PMID 42796509›Full record

ArticleMolecules (Basel, Switzerland)2026

Coumarin Compounds with 6- or 7-(4-Aminobutynyloxy) Substituent: Synthesis, In Vitro Cytotoxicity and In Silico DNA Binding Studies.

Anarkul S Kishkentayeva, Mohammad S Hamad, Victor A Savelyev, Zhasmin A Boyaubayeva, Andrey I Khlebnikov, Andrey G Pokrovsky, Yurii V Gatilov, Almagul S Makhmutova, Elvira E Shults

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anarkul S KishkentayevaSchool of Pharmacy, Karaganda Medical University, Karaganda 100012, Kazakhstan.ORCID 0000-0002-9169-3492
Mohammad S HamadInstitute of Medicine and Medical Technologies, Novosibirsk State University, Pirogova Str., 1, 630090 Novosibirsk, Russia.
Victor A SavelyevN.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Zhasmin A BoyaubayevaSchool of Pharmacy, Karaganda Medical University, Karaganda 100012, Kazakhstan.
Andrey I KhlebnikovKizhner Research Center, Tomsk Polytechnic University, 634050 Tomsk, Russia.ORCID 0000-0002-3022-4510
Andrey G PokrovskyInstitute of Medicine and Medical Technologies, Novosibirsk State University, Pirogova Str., 1, 630090 Novosibirsk, Russia.ORCID 0000-0001-5058-3687
Yurii V GatilovN.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.ORCID 0000-0002-4128-7293
Almagul S MakhmutovaSchool of Pharmacy, Karaganda Medical University, Karaganda 100012, Kazakhstan.ORCID 0000-0002-0194-8739
Elvira E ShultsN.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.ORCID 0000-0002-0761-9696

Funding

Russian Science Foundation 23-73-00077
6 · The paper itself

Abstract

Coumarin compounds are of great interest in drug development research. Various substituents on the coumarin core significantly influence its biological activity. Although a number of coumarins with specific biological properties have already been identified, the ongoing challenge lies in the design and synthesis of novel derivatives with high specificity for pharmacological targets. In this work, 6-(4-aminobut-2-ynyloxy)- and 7-(4-aminobut-2-ynyloxy)-substituted coumarin derivatives were designed and synthesized. As a method for the synthesis of 6- or 7-substituted coumarins (yields 26-98%), a copper-catalyzed one-pot three-component reaction (A

Indexed as

Antineoplastic AgentsCoumarinsDNAAnimalsCell Line, TumorHumansMCF-7 CellsMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsCoumarinsDNAA3-coupling reactioncoumarinscytotoxicityDNAG-quadruplexprop-2-ynyloxycoumarinsumbelliferone

Identifiers

PMID42796509
PMCPMC13609057

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.